Psychological interventions for treatment of inflammatory bowel disease.
Natalia Tiles-Sar, Johanna Neuser, Dominik de Sordi...
https://pubmed.ncbi.nlm.nih.gov/40243391/Actively Recruiting
Led by Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · Updated on 2023-05-31
238
Participants Needed
24
Research Sites
160 weeks
Total Duration
Researchers are evaluating a new approach for adults with moderate to severe ulcerative colitis who need treatment with adalimumab. This Phase IV randomized trial compares standard care with a treat-to-target strategy that includes telemonitoring and patient education. The study aims to assess the impact of using home fecal calprotectin tests and e-monitoring combined with education on disease control by week 48. All participants will initially receive adalimumab with doses starting at 1608040 mg every other week until week 14, then 40 mg every other week until week 26. Dosage may be adjusted up to 80 mg every other week or 40 mg every week based on patient or investigator choice. In addition, patients may receive azathioprine or methotrexate alongside adalimumab until week 38. The study groups differ by follow-up method one group receives standard care with doctor visits every three months, while the other group has e-monitoring, home fecal calprotectin testing, and therapy education. Participants will be involved for about 144 weeks and complete regular assessments including endoscopic exams, clinical evaluations, quality of life surveys, and treatment adherence questionnaires. The study measures success primarily by endoscopic remission at week 48 and also tracks clinical remission, healing rates, patient satisfaction, hospitalizations, colectomies, and safety. Monitoring includes frequent e-monitoring questionnaires and fecal calprotectin testing at home. The trial also evaluates medication compliance and economic outcomes related to treatment.
CONDITIONS
A Trial COmparing staNdard of Care Versus Treat to Target With telemonitoRing and Patient Education in Patients With Ulcerative cOlitis Initiating Adalimumab
X
Xavier Hebuterne, MD PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Lead Sponsor
AbbVie
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 26 weeks
Participants receive Adalimumab injections starting with 160mg, 80mg, then 40mg every other week until Week 14, followed by 40mg every other week until Week 26, combined with telemonitoring and patient education depending on group assignment.
Visits at Weeks 0, 2, 6, 10, 14, 18, 22, and 26 with telemonitoring assessments at Weeks 6, 10, 14, 18, 22, and 26; patient education at Weeks 0, 2, 14, and 26
Duration - Up to Week 144
Participants are monitored through ongoing assessments including telemonitoring, patient education, and clinical evaluations to track treatment outcomes and quality of life until the end of the trial.
Visits at Weeks 34, 38, 42, 48, and additional follow-ups up to Week 144; telemonitoring assessments at Weeks 34, 38, 42, and 48; patient education at Weeks 38
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Natalia Tiles-Sar, Johanna Neuser, Dominik de Sordi...
https://pubmed.ncbi.nlm.nih.gov/40243391/Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Lead Sponsor
AbbVie
Collaborating Sponsor